Identification of a TAP-independent, immunoproteasome-dependent CD8+ T-cell epitope in Epstein-Barr virus latent membrane protein 2

Journal of Virology

Volumn 77, Issue 4, 2003, Pages 2757-2761

  Lautscham, Georg ^a,d   Haigh, Tracey ^a   Mayrhofer, Sabine ^a,e   Taylor, Graham ^a   Croom Carter, Debbie ^a   Leese, Alison ^a   Gadola, Stephan ^b,f   Cerundolo, Vincenzo ^b   Rickinson, Alan ^a   Blake, Neil ^a,c  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

^d MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^e UNIVERSITY OF COLOGNE   (Germany)

^f UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; EPITOPE; HLA A2 ANTIGEN; LATENT MEMBRANE PROTEIN 2; MEMBRANE PROTEIN; PROTEASOME; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS PROTEIN;

ARTICLE; CONTROLLED STUDY; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; HYDROPHOBICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; T LYMPHOCYTE;

ATP-BINDING CASSETTE TRANSPORTERS; CD8-POSITIVE T-LYMPHOCYTES; CYSTEINE ENDOPEPTIDASES; EPITOPES, T-LYMPHOCYTE; HERPESVIRUS 4, HUMAN; HLA-A2 ANTIGEN; HUMANS; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION;

EID: 0037323115     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.77.4.2757-2761.2003     Document Type: Article

References (30)

1. Blake, N., S. Lee, I. Redchenko, W. Thomas, N. Steven, A. Leese, P. Steigerwald-Mullen, M. G. Kurilla, L. Frappier, and A. Rickinson. 1997. Human CD8+ T cell responses to EBV EBNA1: HLA class I presentation of the (Gly-Ala)-containing protein requires exogenous processing. Immunity 7:791-802.
2. Brooks, L., Q. Y. Yao, A. B. Rickinson, and L. S. Young. 1992. Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts. J. Virol. 66:2689-2697.
3. Burrows, S. R., A. Suhrbier, R. Khanna, and D. J. Moss. 1992. Rapid visual assay of cytotoxic T cell specificity utilizing synthetic peptide induced T-cell-T-cell killing. Immunology 76:174-175.
4. Cerundolo, V., A. Benham, V. Braud, S. Mukherjee, K. Gould, B. Macino, J. Neefjes, and A. Townsend. 1997. The proteasome-specific inhibitor lactacystin blocks presentation of cytotoxic T lymphocyte epitopes in human and mouse cells. Eur. J. Immunol. 27:336-341.
5. Chapman, A. L. N., A. B. Rickinson, W. A. Thomas, R. J. Jarrett, J. Crocker, and S. P. Lee. 2001. Epstein-Barr virus-specific cytotoxic T lymphocyte responses in the blood and tumor site of Hodgkin's disease patients: implications for a T-cell based therapy. Cancer Res. 61:6219-6226.
6. Fenteany, G., R. F. Standaert, W. S. Lane, S. Choi, E. J. Corey, and S. L. Schreiber. 1995. Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science 268:726-731.
7. Gabathuler, R., G. Ried, G. Kolaitis, J. Driscoll, and W. A. Jeffries. 1994. Comparison of cell lines deficient in antigen presentation reveals a functional role for TAP-1 alone in antigen processing. J. Exp. Med. 180:1415-1425.
8. Gileadi, U., H. T. Moins-Teisserenc, I. Correa, B. L. Booth, P. R. Dunbar, A. K. Sewell, J. Trowsdale, R. E. Phillips, and V. Cerundolo. 1999. Generation of an immunodominant CTL epitope is affected by proteasome subunit composition and stability of the antigenic protein. J. Immunol. 163:6045-6052.
9. Heemels, M. T., and H. Ploegh. 1995. Generation, translocation, and presentation of MHC class I-restricted peptides. Annu. Rev. Biochem. 64:463-491.
10. Hill, A. B., S. P. Lee, J. S. Haurum, N. Murray, Q. Y. Yao, M. Rowe, N, Signoret, A. B. Rickinson, and A. J. McMichael. 1995. Class I major histocompatibility complex-restricted T lymphocytes specific for Epstein-Barr virus (EBV) nuclear antigens fail to lyse the EBV-transformed B lympho-blastoid lines against which they were raised. J. Exp. Med. 181:2221-2228.
11. Hisamatsu, H., N. Shimbara, Y. Saito, P. Kristensen, K. B. Hendil, T. Fujiwara, E. Takahashi, N. Tanahashi, T. Tamura, A. Ichihara, and K. Tanaka. 1996. Newly identified pair of proteasomal subunits regulated reciprocally by interferon γ. J. Exp. Med. 183:1807-1816.
12. Khanna, R., S. R. Burrows, M. G. Kurilla, C. A. Jacob, I. S. Misko, T. B. Sculley, E. Kieff, and D. J. Moss. 1992. Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development. J. Exp. Med. 176:169-178.
13. Khanna, R., S. R. Burrows, J. M. Nicholls, and L. M. Poulsen. 1998. Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1): evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes. Eur. J. Immunol. 28:451-458.
14. Lautscham, G., S. Mayrhofer, G. Taylor, T. Haigh, A. Leese, A. Rickinson, and N. Blake. 2001. Processing of a multiple membrane spanning Epstein-Barr virus protein for CD8+ T cell recognition reveals a proteasome-dependent, transporter associated with antigen processing-independent pathway. J. Exp. Med. 194:1053-1068.
15. Lee, S. P., R. Tierney, W. A. Thomas, J. M. Brooks, and A. B. Rickinson. 1997. Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy. J. Immunol. 158:3325-3334.
16. Levitskaya, J., M. Coram, V. Levitsky, S. Imreh, P. M. Steigerwald-Mullen, G. Klein, M. G. Kurilla, and M. G. Masucci. 1995. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 375:685-688.
17. Meng, L., R. Mohan, B. H. Kwok, M. Elofsson, N. Sin, and C. M. Crews. 1999. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc. Natl. Acad. Sci. USA 96:10403-10408.
18. Murray, R. J., M. G. Kurilla, J. M. Brooks, W. A. Thomas, M. Rowe, E. Kieff, and A. B. Rickinson. 1992. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies. J. Exp. Med. 176:157-168.
19. Nandi, D., H. Jiang, and J. J. Monaco. 1996. Identification of MECL-1 (LMP-10) as the third IFN-γ-inducible proteasome subunit. J. Immunol. 156:2361-2364.
20. Niedobitek, G. E., E. Kremmer, H. Herbest, L. Whitehead, C. W. Dawson, E. Niedobitek, C. vonOstau, N. Rooney, F. A. Grasser, and L. S. Young. 1997. Immunohistochemical detection of the Epstein-Barr virus encoded latent membrane protein 2A in Hodgkin's disease and infectious mononucleosis. Blood 90:1664-1672.
21. Rickinson, A. B., and E. Kieff. 2001. Epstein-Barr virus, p. 2575-2627. In D. M. Knipe, P. M. Howley, D. E. Griffin, R. A. Lamb, M. A. Martin, B. Roizman, and S. E. Straus (ed.), Fields virology, 4th ed., vol. 2. Lippincott-Williams & Wilkins, Philadelphia, Pa.
22. Rickinson, A. B., and D. J. Moss. 1997. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu. Rev. Immunol. 15:405-431.
23. Rock, K. L., C. Gramm, L. Rothstein, K. Clark, R. Steijn, L. Dick, D. Hwang, and A. L. Goldberg. 1994. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 78:761-771.
24. Rooney, C. M., C. A. Smith, C. Y. Ng, S. K. Loftin, J. W. Sixbey, Y. Gan, D. K. Srivastava, L. C. Bowman, R. A. Krance, M. K. Brenner, and H. E. Heslop. 1998. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 92:1549-1555.
25. Salter, R. D., and P. Cresswell. 1986. Impaired assembly and transport of HLA-A and -B antigens in a mutant TxB cell hybrid. EMBO J. 5:943-949.
26. Sijts, A. J., T. Ruppert, B. Rehermann, M. Schmidt, U. H. Koszinowski, and P. M. Kloetzel. 2000. Efficient generation of a hepatitis B virus cytotoxic T lymphocyte epitope requires the structural features of immunoproteasomes. J. Exp. Med. 191:503-514.
27. Sijts, A. J., S. Standera, R. E. M. Toes, T. Ruppert, N. J. C. M. Beekman, P. A. Van Veelen, F. A. Ossendorp, C. J. M. Melief, and P. M. Kloetzel. 2000. MHC class I antigen processing of an adenovirus CTL epitope is linked to the levels of immunoproteasome in infected cells. J. Immunol. 164:4500-4506.
28. Sijts, A., Y. Yuancheng, K. Janek, S. Kral, A. Paschen, D. Schadenorf, and P. M. Kloetzel. 2002. The role of the proteasome activator PA28 in MHC class I antigen processing. Mol. Immunol. 39:165-169.
29. Sweet, R. M., and D. Eisenberg. 1983. Correlation of sequence hydrophobicities measures similarity in the three-dimensional protein structure. J. Mol. Biol. 171:479-488.
30. Voges, D., P. Zwickl, and W. Baumeister. 1999. The 26S proteasome: a molecular machine designed for controlled proteolysis. Annu. Rev. Biochem. 68:1015-1068.